These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 36653664)

  • 1. Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2 or 3 Breast Cancer.
    Hunt KK; Suman VJ; Wingate HF; Leitch AM; Unzeitig G; Boughey JC; Meric-Bernstam F; Ellis MJ; Olson J
    Ann Surg Oncol; 2023 Apr; 30(4):2111-2118. PubMed ID: 36653664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.
    Ellis MJ; Suman VJ; Hoog J; Lin L; Snider J; Prat A; Parker JS; Luo J; DeSchryver K; Allred DC; Esserman LJ; Unzeitig GW; Margenthaler J; Babiera GV; Marcom PK; Guenther JM; Watson MA; Leitch M; Hunt K; Olson JA
    J Clin Oncol; 2011 Jun; 29(17):2342-9. PubMed ID: 21555689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
    Ellis MJ; Suman VJ; Hoog J; Goncalves R; Sanati S; Creighton CJ; DeSchryver K; Crouch E; Brink A; Watson M; Luo J; Tao Y; Barnes M; Dowsett M; Budd GT; Winer E; Silverman P; Esserman L; Carey L; Ma CX; Unzeitig G; Pluard T; Whitworth P; Babiera G; Guenther JM; Dayao Z; Ota D; Leitch M; Olson JA; Allred DC; Hunt K
    J Clin Oncol; 2017 Apr; 35(10):1061-1069. PubMed ID: 28045625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial.
    Ma CX; Suman VJ; Sanati S; Vij K; Anurag M; Leitch AM; Unzeitig GW; Hoog J; Fernandez-Martinez A; Fan C; Gibbs RA; Watson MA; Dockter TJ; Hahn O; Guenther JM; Caudle A; Crouch E; Tiersten A; Mita M; Razaq W; Hieken TJ; Wang Y; Rimawi MF; Weiss A; Winer EP; Hunt KK; Perou CM; Ellis MJ; Partridge AH; Carey LA
    JAMA Oncol; 2024 Mar; 10(3):362-371. PubMed ID: 38236590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study.
    Iwata H; Masuda N; Yamamoto Y; Fujisawa T; Toyama T; Kashiwaba M; Ohtani S; Taira N; Sakai T; Hasegawa Y; Nakamura R; Akabane H; Shibahara Y; Sasano H; Yamaguchi T; Sakamaki K; Bailey H; Cherbavaz DB; Jakubowski DM; Sugiyama N; Chao C; Ohashi Y
    Breast Cancer Res Treat; 2019 Jan; 173(1):123-133. PubMed ID: 30242578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after neoadjuvant treatment, and FES-PET as potential significant biomarkers.
    Park JH; Kang MJ; Ahn JH; Kim JE; Jung KH; Gong G; Lee HJ; Son BH; Ahn SH; Kim HH; Shin HJ; Moon DH; Kim SB
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):685-95. PubMed ID: 27491481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy.
    Krainick-Strobel UE; Lichtenegger W; Wallwiener D; Tulusan AH; Jänicke F; Bastert G; Kiesel L; Wackwitz B; Paepke S
    BMC Cancer; 2008 Feb; 8():62. PubMed ID: 18302747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J
    Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term outcomes of neoadjuvant hormonal therapy versus neoadjuvant chemotherapy in breast cancer: systematic review and meta-analysis of randomized controlled trials.
    Huang L; Xu AM
    Expert Rev Anticancer Ther; 2017 Apr; 17(4):327-334. PubMed ID: 28271747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges in the endocrine management of breast cancer.
    Mouridsen HT; Rose C; Brodie AH; Smith IE
    Breast; 2003 Aug; 12 Suppl 2():S2-19. PubMed ID: 14659138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in Neoadjuvant Endocrine Therapy Use and Impact on Rates of Breast Conservation in Hormone Receptor-Positive Breast Cancer: A National Cancer Data Base Study.
    Chiba A; Hoskin TL; Heins CN; Hunt KK; Habermann EB; Boughey JC
    Ann Surg Oncol; 2017 Feb; 24(2):418-424. PubMed ID: 27663568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients--a phase II trial.
    Fontein DB; Charehbili A; Nortier JW; Meershoek-Klein Kranenbarg E; Kroep JR; Putter H; van Riet Y; Nieuwenhuijzen GA; de Valk B; Terwogt JM; Algie GD; Liefers GJ; Linn S; van de Velde CJ
    Eur J Cancer; 2014 Sep; 50(13):2190-200. PubMed ID: 24970786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors affecting locoregional recurrence in breast cancer patients undergoing surgery following neoadjuvant treatment.
    Chou HH; Chung WS; Ding RY; Kuo WL; Yu CC; Tsai HP; Shen SC; Chu CH; Lo YF; Chen SC
    BMC Surg; 2021 Mar; 21(1):160. PubMed ID: 33757489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer.
    Grassadonia A; Di Nicola M; Grossi S; Noccioli P; Tavoletta S; Politi R; Angelucci D; Marinelli C; Zilli M; Ausili Cefaro G; Tinari N; De Tursi M; Iezzi L; Cioffi P; Iacobelli S; Natoli C; Cianchetti E
    Ann Surg Oncol; 2014 May; 21(5):1575-82. PubMed ID: 24522992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial.
    Olson JA; Budd GT; Carey LA; Harris LA; Esserman LJ; Fleming GF; Marcom PK; Leight GS; Giuntoli T; Commean P; Bae K; Luo J; Ellis MJ
    J Am Coll Surg; 2009 May; 208(5):906-14; discussion 915-6. PubMed ID: 19476859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Locoregional and Overall Recurrence After Neaodjuvant Endocrine Therapy Versus Chemotherapy in Postmenopausal Women With Estrogen Receptor+ HER2- Breast Cancer.
    Wright JL; Saigal K; Reis IM; Zhao W; Takita C; Ambros T; Saeed AM; Sujoy V; Hurley J
    Am J Clin Oncol; 2017 Oct; 40(5):490-497. PubMed ID: 26017482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant endocrine therapy of breast cancer: which patients would benefit and what are the advantages?
    Takei H; Kurosumi M; Yoshida T; Hayashi Y; Higuchi T; Uchida S; Ninomiya J; Oba H; Inoue K; Nagai S; Tabei T
    Breast Cancer; 2011 Apr; 18(2):85-91. PubMed ID: 21104350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness-a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer.
    Madeira M; Mattar A; Logullo AF; Soares FA; Gebrim LH
    BMC Cancer; 2013 Sep; 13():425. PubMed ID: 24047421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
    Semiglazov VF; Semiglazov VV; Dashyan GA; Ziltsova EK; Ivanov VG; Bozhok AA; Melnikova OA; Paltuev RM; Kletzel A; Berstein LM
    Cancer; 2007 Jul; 110(2):244-54. PubMed ID: 17538978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.